Peptide/Protein Ingredients TRIZ Cases

Vitrified VEGF in water-stable and biodegradable polymer layers extends release time and preserves wound-healing activity at body temperature.

Viral vectors co-expressing BMP2 and IL-1Ra promote bone growth while limiting inflammatory response and donor-site drawbacks.

Oral hydrogel composites bind PFAS, nitrosamines, nitrates, carcinogens, and food dyes in the digestive tract without systemic absorption.

Combining TUSC2 therapy with anti-PD1 boosts NK and CD8+ T cells, reduces suppressive immune cells, and improves tumor regression.

Stapled peptides block FOXP3 domains to suppress Treg immunosuppression while sparing activated cytotoxic T cells.

Anchored cytokines on engineered immune cells boost CAR-T survival and cytotoxicity while reducing lymphodepletion needs and cytokine release risk.

Antibody-linked protection enzymes neutralize cytotoxic drugs near healthy cells, reducing side effects and widening the chemotherapy window.

Multivalent TIGIT-binding peptides on nanoparticle cores improve receptor binding and extend plasma circulation beyond free peptides.

An endoglycosidase hydrolase enables subcutaneous anti-PD-1 or PD-L1 delivery, reducing infusion burden while preserving treatment reliability.

NK cells first induce MHC-I expression in low-MHC-I tumors, enabling follow-on T cell targeting and stronger anti-tumor activity.

ICAM1-targeted membrane-coated nanoparticles deliver pro-angiogenic payloads to ischemic tissue, improving perfusion in PAD without invasive intervention.

Bone-anchored IL-6 family cytokine conjugates sustain signaling to restore muscle function and exercise capacity without implanted infusion pumps.

Controlled anti-PD-1 formulations with rHuPH20 limit CDR oxidation and deamidation while preserving hyaluronidase activity and efficacy.

Annelid extracellular hemoglobin inhibits C3 convertases to limit ischemia/reperfusion injury and antibody-mediated transplant rejection.

Antigen conjugates with liver-targeting moieties use receptor-mediated uptake to improve tolerance induction and reduce unwanted immune responses.

Single-pass EV membrane proteins improve cargo loading while leaving room for targeting and endosomal escape modules in intracellular delivery.

Personalized neoantigen vaccination combined with anti-PD-1 and platinum chemotherapy boosts tumor-specific immunity while limiting autoimmunity risk.

Controlled PD-1 antibody oxidation and deamidation with PH20 supports stable hyaluronidase activity and better subcutaneous delivery.

Engineered IL-2 muteins boost IL-2Rβ binding while limiting CD25 activity, improving anti-PD-1 combination therapy for cancer.

Targeting NRP-1 on PD1+ CD8+ T cells helps overcome resistance to PD-1 blockade and strengthens anti-tumor immune responses.

Local purified collagenase breaks down fibroid collagen to shrink uterine fibroids while avoiding invasive surgery and limiting systemic side effects.

Co-expressing IL-7 and CCL19 helps mesothelin-targeting CAR immune cells accumulate in tumors, persist longer, and suppress recurrence.

Targeting the ADAM8 disintegrin domain blocks both protease and adhesion functions, helping limit tumor migration, invasion, and metastasis.

Isolated PHF6 or DPF3b PHD domains target histone marks to inhibit cancer cell proliferation while avoiding writer-driven side effects.

Disease-specific ECM nanobodies overcome insoluble, crosslinked matrix targets to improve in vivo imaging and agent delivery at tumors and other lesions.

GM-CSF gene-inactivated CAR-T cells plus anti-hGM-CSF antibodies curb CRS and neurotoxicity while preserving anti-tumor activity.

A propylene-ethylene copolymer inner surface cuts NGF adsorption, keeping aqueous formulations stable at room temperature without coatings or additives.

Rigid EAAAK linkers and hydrophilic substitutions boost membrane fusion inhibition, extending antiviral activity across HIV and other viruses.

Specific anti-renalase antibodies improve renalase detection selectivity and block signaling to suppress melanoma and pancreatic cancer cells.

A hydrocarbon-fluorocarbon emulsion encapsulates proteins in polymer microparticles to prevent degradation, aggregation, and leakage.

Small LAG-3 binding peptides inhibit checkpoint function, activate immune cells, and offer a lower-cost alternative to antibody therapy.

Active-site substitutions and terminal truncation shift hyaluronidase toward neutral pH activity, improving use in skin and other therapies.

Targeted mutations at residues 108 and 139 improve fucosyltransferase labeling of complex substrates on cell membranes and boost enzyme activity.

Using allogeneic MAIT cells with CAR expression enables pre-manufactured immunotherapy while avoiding graft-versus-host disease and variability.

Short peptides target prefusion RSV fusion protein to block viral entry and lower viral load with a lower-cost alternative to antibodies.

Human-like oligosaccharide-linked GAA improves respiratory and muscle function in late-onset Pompe disease with fewer adverse events.

Engineered NK cells use CD38-targeting CARs plus homing and cytotoxicity tuning to attack tumors without antigen priming while sparing normal cells.

Engineered T cell receptors target the HPV16 E7 peptide on cancer cells, improving selective killing while limiting damage to normal cells.

Salt-tuned aqueous conditions help sortase F join proteins and small molecules faster while preserving sequence-specific conjugation.

Low-dose monthly degarelix suppresses testosterone rapidly while reducing spike risk and side effects such as cardiac disorders and UTIs.

Multi-epitope anti-HIV-1 antibodies improve neutralization of diverse and autologous viral strains that evade existing bNAbs.

A bacterial pore-forming MakA protein targets tumor membranes and β-catenin signaling to kill colorectal cancer cells with fewer side effects.

Thin-section MDCT with iterative reconstruction reveals and quantifies airway mucus plugs to guide personalized asthma and COPD treatment.

An aromatic-linker amphiphilic copolymer boosts hydrophobic drug loading and keeps nanomicelles stable without toxic solubilizers.

Cyclic peptide IL-23R inhibitors use structural modifications to preserve binding while improving oral bioavailability and in vivo half-life.

Linear peptide analogs improve apelin receptor antagonism by avoiding agonist effects while simplifying synthesis for glioblastoma treatment.

Targeted CRISPR cuts in APLP2 introns enable donor knock-in while preserving native gene expression and protein secretion.

A protease-cleavable masked IFNα conjugate limits normal-tissue toxicity while restoring anti-tumor activity inside the tumor microenvironment.

Targeted antithrombin dosing can limit infarct volume and inflammation in ischemic stroke while avoiding added bleeding risk.

An IgG-based conditioning step followed by enzyme IgG inactivation reduces graft rejection while shortening immune recovery time.